

Resource Summary Report

Generated by [NIF](#) on Sep 2, 2026

Ablynx

RRID:SCR_002940

Type: Tool

Proper Citation

Ablynx (RRID:SCR_002940)

Resource Information

URL: <http://www.Ablynx.com>

Proper Citation: Ablynx (RRID:SCR_002940)

Description: A biopharmaceutical company engaged in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins based on single-domain antibody fragments, for a range of serious life-threatening human diseases including inflammation, hematology, oncology and pulmonary disease.

Abbreviations: Ablynx

Resource Type: material service resource, production service resource, reagent manufacture, service resource

Keywords: nanobody, protein, antibody fragment, human disease, oncology, hematology, tumor, blood, therapy, therapeutic, pharmaceutical, drug product, drug

Related Condition: Inflammation, Cancer, Pulmonary disease, Thrombosis, Alzheimer's disease, Rheumatoid arthritis, Osteoporosis, Thrombotic thrombocytopenic purpura, Respiratory syncytial virus

Resource Name: Ablynx

Resource ID: SCR_002940

Alternate IDs: nif-0000-30052

Record Creation Time: 20220129T080216+0000

Record Last Update: 20260829T182137+0000

Ratings and Alerts

No rating or validation information has been found for Ablynx.

No alerts have been found for Ablynx.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ben Abderrazek R, et al. (2022) Neutralizing Dromedary-Derived Nanobodies Against BotI-Like Toxin From the Most Hazardous Scorpion Venom in the Middle East and North Africa Region. *Frontiers in immunology*, 13, 863012.

Coddens A, et al. (2020) An innovative method for characterizing neutralizing antibodies against antibody-derived therapeutics. *Journal of immunological methods*, 487, 112896.

Bauché D, et al. (2020) Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions. *Journal for immunotherapy of cancer*, 8(2).

Weiss RA, et al. (2019) Nanobodies that Neutralize HIV. *Vaccines*, 7(3).

Kazemi-Lomedasht F, et al. (2018) Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function. *Iranian journal of basic medical sciences*, 21(3), 260.

Veugelen S, et al. (2017) Screening and Characterization Strategies for Nanobodies Targeting Membrane Proteins. *Methods in enzymology*, 584, 59.

Arbabi-Ghahroudi M, et al. (2017) Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook. *Frontiers in immunology*, 8, 1589.

Van Audenhove I, et al. (2016) Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer. *EBioMedicine*, 8, 40.

Zhu M, et al. (2014) Streptavidin-biotin-based directional double Nanobody sandwich ELISA for clinical rapid and sensitive detection of influenza H5N1. *Journal of translational medicine*, 12, 352.

Elvin JG, et al. (2013) Therapeutic antibodies: market considerations, disease targets and bioprocessing. *International journal of pharmaceuticals*, 440(1), 83.

Boruah BM, et al. (2013) Single domain antibody multimers confer protection against rabies infection. *PloS one*, 8(8), e71383.

Elsadek B, et al. (2012) Impact of albumin on drug delivery--new applications on the horizon. *Journal of controlled release : official journal of the Controlled Release Society*, 157(1), 4.

Kratz F, et al. (2012) Clinical impact of serum proteins on drug delivery. *Journal of controlled release : official journal of the Controlled Release Society*, 161(2), 429.

Wesolowski J, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. *Medical microbiology and immunology*, 198(3), 157.

Dimitrov DS, et al. (2009) Therapeutic antibodies: current state and future trends--is a paradigm change coming soon? *Methods in molecular biology (Clifton, N.J.)*, 525, 1.

Saerens D, et al. (2008) Single-domain antibodies as building blocks for novel therapeutics. *Current opinion in pharmacology*, 8(5), 600.

Hmila I, et al. (2008) VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin Aahl'. *Molecular immunology*, 45(14), 3847.

Harmsen MM, et al. (2007) Properties, production, and applications of camelid single-domain antibody fragments. *Applied microbiology and biotechnology*, 77(1), 13.